The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2020

Filed:

Nov. 14, 2016
Applicants:

LA Jolla Institute for Allergy and Immunology, La Jolla, CA (US);

Universiteit Gent, Ghent, BE;

Vib Vzw, Ghent, BE;

Inventors:

Dirk Zajonc, San Diego, CA (US);

Serge Van Calenbergh, Ghent, BE;

Dirk Elewaut, Ghent, BE;

Joren Guillaume, Ghent, BE;

Assignees:

La Jolla Institute for Allergy and Immunology, La Jolla, CA (US);

Universiteit Gent, Ghent, BE;

VIB VZW, Ghent, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 15/04 (2006.01); A61K 47/65 (2017.01); A61P 37/04 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); A61K 31/7028 (2006.01); A61K 31/739 (2006.01); C07H 15/18 (2006.01); C07H 15/06 (2006.01);
U.S. Cl.
CPC ...
C07H 15/04 (2013.01); A61K 31/7028 (2013.01); A61K 31/739 (2013.01); A61K 47/65 (2017.08); A61P 31/12 (2018.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07H 15/06 (2013.01); C07H 15/18 (2013.01);
Abstract

The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of α-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.


Find Patent Forward Citations

Loading…